Opella: New study demonstrates successful cough treatment extends beyond symptom relief

PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic relief.

With most consumers1 making treatment decisions in the pharmacy, the pharmacist's recommendation plays a pivotal role in helping patients return to their normal routines and make the moment theirs again.

Key Findings:

- Fast Relief from the First Dose: Patients reported fast relief from the very first dose of treatment2, with data showing improvements in daily functioning from the first day of treatment, allowing them to rapidly start regaining control over their day.

- Restored Social Engagement: A clinically meaningful improvement in the social impact of cough was achieved within 72 hours, reflecting patients' ability to engage more comfortably in conversations and everyday social activities.

- Improved Sleep Quality: Sleep disruption is a primary patient concern. After just 48 hours, difficulty falling asleep, staying asleep, and sleep-related tiredness scores improved significantly, with the percentage of patients reporting these challenges dropping by 59%, 56% and 55% in each category.

Milena Leone, Global Brand General Manager, Opella.

"When a cough disrupts daily routines, effective and timely care is essential. This study provides valuable, real-world evidence that Mucosolvan and Bisolvon goes beyond managing the physical symptom; by delivering fast-acting relief from the first dose, it helps people move past the disruption of cough and resume their daily lives more quickly."

About the Study

The RWE Cough Study was a prospective, observational study conducted in Italy with adult consumers who had purchased Mucosolvan (Ambroxol) or Bisolvon (Bromhexine) for an acute chesty cough. The study evaluated daily effectiveness and quality of life impacts over a seven-day period using validated tools, including the Cough Severity Diary (CSD) and the Leicester Cough Questionnaire (LCQ).

For more information or to review the findings in full, go to p. 79 here.

MAT-GLB-2605783-v1.0-10/2026

1. In Germany, 58% of consumers make their cough and cold treatment decisions in-store.

2. After first intake, 53% (41%) of bromhexine (ambroxol) users agreed/strongly agreed they felt immediately relieved, and 57% and 44%, respectively, reported relief from the urge to cough. 

Source: I&P Tracker 2025, Dive SO Units WWP MAT Dec'25, "Understand the Shopper Journey on the C&C Category to Drive an Omnichannel Strategy", Germany, May 2023.

Contact: [email protected]

Share this article

NicholsMD Introduces Acorn YOU™ Secretome at The Hair Lab™ in Greenwich

The Connecticut dermatology practice expands its physician-led, concierge approach to hair and scalp care.

GREENWICH, Conn., Oct. 14, 2026 /PRNewswire/ -- NicholsMD, a Connecticut dermatology practice founded by board-certified dermatologist Dr. Kim Nichols, is launching Acorn YOU™ Secretome at The Hair Lab™, its dedicated destination for personalized hair and scalp care at its Greenwich flagship. The addition gives The Hair Lab™ team another professional option to discuss with patients based on their hair and scalp concerns.

YOU™ Secretome is created using a patient's own preserved hair follicle cells. Acorn describes it as a cell-free blend of signaling molecules - including exosomes, growth factors, peptides, and proteins - that help cells communicate. These molecules are intended to support the scalp's follicle environment and natural hair renewal, with the goal of promoting stronger, thicker-looking hair and improving hair amount and quality. Because the product is made from a patient's own cells, it offers a highly tailored approach to hair and scalp care.

A Dedicated Destination for Hair and Scalp

At NicholsMD, YOU™ Secretome will be part of the Hair Lab's personalized approach to the hair you want, made simple. A consultation may include a detailed scalp and follicle analysis to help the care team understand a patient's concerns and discuss appropriate options. The Hair Lab™ offers a range of professional and at-home hair and scalp services, including PRP (platelet-rich plasma), HydraScalp treatments, laser hair removal, and home-care products such as Revian. Recommendations are curated by Dr. Nichols and her team for each individual; YOU™ Secretome is one option within that broader conversation.

"We know skincare is deeply personal, and hair care deserves that same thoughtful attention," said Dr. Kim Nichols, board-certified dermatologist and founder of NicholsMD. "We created The Hair Lab™ to give patients a dedicated place to discuss their hair and scalp concerns with our team. Acorn YOU™ Secretome is a compelling addition because it is made using a patient's own preserved hair follicle cells, giving us another distinctive option to discuss as part of their care."

The launch reflects NicholsMD's concierge-level approach across hair and skincare, bringing expert guidance and thoughtful recommendations together in one setting.

Bringing Acorn's Science to The Hair Lab™

Acorn Biolabs founder and Chief Executive Officer Dr. Drew Taylor recently visited NicholsMD to meet with Dr. Nichols and the team and share more about the company's cell-to-secretome platform. "Your own cells will one day be the most important currency in medicine. Acorn exists to collect, store and prepare you to leverage your best cells for future medical innovations," said Dr. Drew Taylor, founder and Chief Executive Officer of Acorn Biolabs. Taylor's doctoral research into hair follicle stem cells became the scientific foundation for Acorn and its YOU™ Secretome product. His visit provided an opportunity for the NicholsMD team to learn more about the product and discuss its place within the Hair Lab's professional protocols.

Patients looking to support fuller-looking hair, interested in learning more about YOU™ Secretome, or wanting to explore options for unwanted hair can schedule a consultation with the NicholsMD team to discuss goals and available services.

About NicholsMD of Greenwich

Founded in 2013, NicholsMD of Greenwich is the first and only boutique dermatology practice in Greenwich, Connecticut. Led by board-certified dermatologist Dr. Kim Nichols, the practice has become a premier destination for medical, cosmetic, and regenerative dermatology, offering concierge-level care across three Fairfield County locations. NicholsMD specializes in advanced injectables with natural-looking results, regenerative treatments, and precision anti-aging rooted in science and artistry.

About Acorn Biolabs

Acorn Biolabs collects and stores a person's own hair follicle cells in a short, non-surgical appointment. Those cells produce YOU™ Secretome, a bio-identical regenerative solution that professionals use in skin, hair and scar protocols. Because it's made from the individual's own cells, it's autologous, not donor-derived. Currently used topically in aesthetics, with work underway toward an approved injectable version.

SOURCE NicholsMD of Greenwich

Share this article

Trail-Ready Adventures Await: Akins Ford Opens Order Banks for 2027 Ford Bronco Models

Built to Conquer the Trails: Akins Ford Opens Official Online Order Banks for the Highly Anticipated 2027 Ford Bronco SUV

WINDER, Ga., Oct. 14, 2026 /PRNewswire/ -- Outdoor enthusiasts and off-road drivers across Georgia can now secure their ultimate adventure SUV as Akins Ford officially opens its digital order bank for the new model year. Customers wondering where to order the 2027 Ford Bronco can now submit their custom reservations directly through the dealership's dedicated online portal.

Where to Order the 2027 Ford Bronco in Georgia

By visiting the Akins Ford 2027 Bronco order page, buyers reserve their ideal trim level, paint color, and off-road packages before factory production begins. Because securing a high-demand 4x4 SUV requires early planning, submitting an online order delivers priority placement in the build queue.

Key advantages of placing a 2027 Bronco order through Akins Ford include:

- Custom Vehicle Configuration: Drivers select their exact engine, transmission, door layout, and equipment group directly from the factory line.

- Transparent Pricing: Every custom order comes with clear, competitive pricing and zero hidden dealer markups.

- Nationwide Ordering Power: As one of the largest Ford hubs in the nation, Akins Ford receives substantial inventory allocations for faster fulfillment.

Advanced Capability Meets Modern Technology

The 2027 Ford Bronco continues its legacy as a premier off-road SUV, offering removable doors and roof panels alongside standard High-Performance Off-Road Stability Suspension systems. Furthermore, available G.O.A.T. Modes™ allow drivers to traverse mud, sand, rocks, and steep inclines with total control. Inside the cabin, modern SYNC® 4 technology keeps navigation and smartphone apps accessible across remote trails.

"Custom ordering a new Bronco gives our customers complete control over their vehicle's look and off-road capability right from the factory," says Marketing Manager Tanner Maloof. "Whether drivers want a trail performer or an extreme rock crawler, our order page makes the reservation process fast and simple."

Reserve Your 2027 Ford Bronco Today at the Number 1 Bronco Dealership in the Nation

Buyers can be confident in ordering through Akins Ford, listed as the number one Bronco dealer in the nation. Adventure seekers ready to build their custom SUV can visit Akins Ford online or stop by the showroom in Winder, GA. As the nation's premier Ford dealership, Akins Ford delivers top-tier customer service, custom vehicle upfitting, and competitive financing to help every driver hit the trail in confidence.

About Akins Ford

Akins Ford Chrysler Dodge Jeep Ram is a full-service automotive dealership located at 220 West May Street, Winder, GA 30680, proudly serving customers across Atlanta, Athens, Buford, Gwinnett County, and the greater Southeast. As one of the largest Ford dealers in the country, Akins Ford offers new and used Ford, Chrysler, Dodge, Jeep, and Ram vehicles, along with certified service, parts, mobile service, commercial and fleet truck sales, collision repair, and custom truck builds through Wild Willies Custom Accessories. Learn more at akinsford.com or call (770) 867-9136.

PR Contact:

Tanner Maloof 

Phone number:

770-868-5262

Email: 

[email protected]

SOURCE Akins Ford

Share this article

XPENG CEO He Xiaopeng Calls for Deeper Global Collaboration at the 2026 Paris Automotive Summit, Highlighting "XPENG AI Engineering"

- Mr. He Xiaopeng, Chairman & CEO, becomes the first Chinese automotive CEO to deliver a keynote in the history of the Paris Automotive Summit, calling for greater industry collaboration as AI, electrification and globalization reshapes the automotive sector.

- Mr. He Xiaopeng introduced XPENG AI Engineering, calling for open collaboration and opening XPENG's full-stack technologies and engineering capabilities to global partners, from vehicle platforms to Physical AI.

- XPENG highlighted NGP which is aiming for global market expansion in 2027, alongside clear milestones for its humanoid robot, IRON, targeting mass production in late 2026, initial deliveries in H1 2027, and a European rollout in H2 2027.

PARIS, Oct. 14, 2026 /PRNewswire/ -- Mr. He Xiaopeng, Chairman & CEO of XPeng Inc. ("XPENG" or the "Company,"NYSE: XPEV; HKEX: 9868), a leading global Physical AI company, today called for deeper collaboration across the global automotive industry, as he became the first Chinese automotive CEO to deliver a keynote in the history of the Paris Automotive Summit.

Speaking to automotive industry leaders in Paris, Mr. He outlined how AI, electrification and smart technologies are reshaping the automotive industry, creating new opportunities for technology collaboration across the sector.

The theme of his keynote speech was "Navigating the AI Era: Open Collaboration for a Smarter Future," where he outlined XPENG AI Engineering, XPENG's strategy to combine its Physical AI technology with deeper ecosystem partnerships across Europe and globally.

He emphasized that no single manufacturer holds all the advantages required for the next generation of smart mobility. To accelerate this transition, XPENG is opening its in-house tech stack and engineering resources to key international partners.

Open Technology Collaboration for the AI Era: XPENG AI Engineering

XPENG's approach to collaboration is rooted in its evolution as a Physical AI company, with full-stack technologies spanning chips, models and applications across intelligent vehicles, robotaxis, humanoid robots and flying cars. In intelligent driving, XPENG highlighted NGP powered by VLA 2.0, designed to advance directly from L2 to L4 and deliver the same core capability across China and Europe, as the company prepares to bring advanced intelligent driving to global markets in 2027.

XPENG is also advancing the commercialization of its humanoid robot, IRON, with mass production targeted for late 2026, deliveries beginning in the first half of 2027, and a European rollout planned for the second half of 2027.

As AI expands into the physical world, XPENG believes industry transformation will be driven both from within and beyond automotive. To usher in this new era, XPENG is opening its proprietary technologies and engineering toolchains to global partners - spanning vehicle platforms, E/E architecture, batteries, e-drives, and modular innovations like the AI BOX, Turing AI chip, and Turing physical world foundation model.

Through XPENG AI Engineering, the company is pursuing a model built around complementary strengths, flexible collaboration and independent innovation, enabling partners to co-develop differentiated products while building their own technology capabilities over time.

As a proven example of this mutually beneficial approach, Mr. He highlighted XPENG's strategic collaboration with Volkswagen Group, which brings together XPENG's intelligent-driving and software capabilities with Volkswagen's vehicle engineering and testing expertise.

This latest development builds on XPENG's continued investment in technology and talent. In the first half of 2026, XPENG invested approximately €770 million in R&D.

"Partnership starts with trust, and after trust comes openness," said Mr. He. "We welcome global partners to work with us, learn from each other and bring our strengths together. To bring technology to life and build the future together."

In Europe, For Europe, With Europe

Mr. He also reinforced XPENG's long-term "In Europe, For Europe, With Europe" commitment, centered on producing in Europe, designing for European users and partnering with the region's industrial ecosystem.

XPENG has put four models into production in Europe within one year, including the G6, G9, P7+ and the latest G9L. Its European R&D center serves as a hub for EU homologation and certification, language and interaction localization, intelligent-driving validation, European chassis and handling tuning, and charging-network integration.

XPENG continues to deepen collaboration across Europe's automotive and technology ecosystem, working with local partners as it expands its capabilities in the region.

ENDS

About XPENG

XPENG is a leading global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. Through in-house R&D, XPENG has developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. This unified technology foundation powers an expansive product portfolio of smart EVs, robotaxis and humanoid robots, advancing the deployment of Physical AI at scale.

Headquartered in Guangzhou, China, XPENG is dual-primary listed on the New York Stock Exchange and the Hong Kong Stock Exchange. With global capabilities across R&D, manufacturing, sales and services, XPENG drives continuous technological innovation and fosters an open Physical AI ecosystem, making life smarter, safer and better for users worldwide.

For more information, please visit https://www.xpeng.com/.

SOURCE XPENG

Share this article

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Netcapital Inc. (NASDAQ: NCPL) between December 15, 2021 and September 3, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026 in the securities class action first filed by the Firm.

So what: If you purchased Netcapital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Netcapital class action, go to https://rosenlegal.com/cases/netcapital-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Over the Class Period, Netcapital improperly recognized material revenues from what were, in reality, sham consulting agreements with entities controlled by Defendant John Fanning; (2) The consulting agreements were backdated and in some cases forged, and Netcapital Advisors provided little if any meaningful consulting services; (3) The Portfolio Company transactions were improperly undisclosed related-party transactions involving John Fanning; (4) Netcapital's certifications pursuant to the Sarbanes-Oxley Act of 2002 were false; and (5) as a result, defendants' statements about Netcapital's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Netcapital class action, go to https://rosenlegal.com/cases/netcapital-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY  10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected] 

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

State Street shares fell approximately 7% by market open on October 14, 2026, after third-quarter revenue of $4.00 billion came in below the roughly $4.03 billion Wall Street expected. An investigation into potential securities law violations has been opened.

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Investors in State Street Corporation (NYSE: STT) watched their shares drop approximately 7% on October 14, 2026, after the Company reported third-quarter revenue of $4.00 billion, short of the roughly $4.03 billion analysts expected. If STT shares in your account lost value on the report, act now. Shareholders who lost money on State Street are encouraged to submit their losses for review today. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

Analysts had projected third-quarter revenue of roughly $4.03 billion. State Street reported approximately $4.00 billion -- a shortfall of about $30 million to $60 million against the consensus range. Fee revenue of approximately $3.14 billion particularly fell shy of the estimated $3.18 billion analysts had projected.

SueWallSt notifies investors of a pending investigation into whether State Street may not have adequately disclosed fee-revenue trends to investors before the October 14 report. The investigation also concerns whether shareholders who bought STT may have claims for potential securities law violations.

If you bought State Street stock and are now holding a loss, talk to an attorney about your STT losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the STT Investigation

Q: Who is eligible to participate in the STT investigation?A: Investors who purchased STT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did STT stock drop?A: Shares opened at about $161.90 on October 14, 2026, a decline of approximately $12.20, or 7%, from its closing price on October 13, 2026. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns statements made before the October 14, 2026 third-quarter disclosure. The firm is examining whether those statements caused investors to purchase State Street securities at inflated prices.

Q: What do STT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my STT shares? Can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought STT and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

The yield on CoreWeave's unsecured bonds reportedly reached 15% on October 13, 2026. The next day, the stock was dropping by nearly the same figure. The investigation concerns whether CoreWeave adequately disclosed the borrowing-cost risk tied to its debt-funded expansion.

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- CoreWeave, Inc. (NASDAQ: CRWV) shares opened at $71.79, a decline of about 7.74% from the previous day's closing price of $77.81, as reports that the yield on the Company's unsecured bonds reportedly touched 15% developed. By midday, the stock price had fallen more than 15%. If you bought CRWV shares and lost money, you may have legal rights, and the investigation is underway now. Shareholders who suffered losses are encouraged to review your potential recovery options now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

This development follows CoreWeave's decision to increase its full-year CapEx guidance during its second quarter earnings call on August 11, 2026 from a range of $31 billion to $35 billion, to $35 billion to $39 billion, an increase of about 10.8% at the midpoint and significantly more than double the $14.9 billion it spent in 2025. Analysts have called the investment cycle "more pronounced than expected."

CoreWeave's buildout of data centers, GPUs and power capacity has been funded in large part with debt, and its interest expense has risen sharply. Before the bond selloff, CRWV had already fallen more than 45% below its 52-week high of $150.40. SueWallSt notifies shareholders of an investigation into potential securities law violations, including whether CoreWeave may not have adequately disclosed the borrowing-cost and refinancing risk tied to its expansion.

CoreWeave shareholders who lost money are encouraged to request a no-cost review of their CRWV losses or call (888) SueWallSt.

WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the CRWV Investigation

Q: Who is eligible to participate in the CRWV investigation? A: Investors who purchased CRWV stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did CRWV stock drop? A: Coreweave opened at $71.79 on October 14, 2026, down approximately $6.02 per share, or about 7.74% from its previous closing price. The stock continued to decline, reaching a more than 15% decline by midday as the market digested the news that CoreWeave's unsecured bonds reached 15%. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Who is conducting the CRWV investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased CRWV securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do CRWV investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my CRWV shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CRWV and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

Pilots in Seattle and Boise Demand Fair Contract After Years of Stalled Negotiations

SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Nearly 650 pilots at Horizon Air, represented by Teamsters Local 1224, held an informational picket today in Seattle and Boise, calling on the airline to end years of delay tactics and agree to a fair contract that provides industry-standard compensation.

Teamsters pilots at Horizon have been negotiating for nearly four years for an agreement that addresses critical issues including wages, staffing and training shortages, and operational concerns that continue to impact both employees and the airline's future.

As a subsidiary of Alaska Air Group, Horizon pilots perform nearly the same amount of flying as their counterparts at Alaska Airlines. Despite those responsibilities, Horizon pilots' pay continues to fall behind industry standards due to the company's refusal to negotiate a fair agreement.

"Our pilots are the backbone of Horizon's operation," said Henry Simkins, Chair of Local 1224's Horizon Executive Council. "They continue to deliver safe and reliable service every day while management drags its feet on a contract that reflects their contribution and value. The same mismanagement has created operational challenges throughout the airline, and that dysfunction has become impossible to ignore in bargaining. Our members deserve better and they're tired of being told to wait."

In addition to the informational picket, Horizon pilots will conduct a vote of no confidence in Carlos Zendejas, Senior Vice President of Operations at Horizon.

Pilots at Horizon say chronic staffing shortages, inconsistent application of company policies and procedures, and a growing reliance on pilots to compensate for operational shortcomings are reasons for the vote. These issues have persisted throughout contract negotiations and have contributed to a significant erosion of trust in company leadership.

"Every day, Horizon pilots are expected to do more with less," said Jason Welch, a Horizon pilot and member of Local 1224. "We've watched these challenges persist for years, yet management refuses to address the issues that matter most to us. Enough is enough — it's time for the company to start delivering real solutions."

Teamsters Local 1224 represents aviation professionals throughout the United States, including flight crewmembers at ABX Air, Cape Air, Horizon Air, Omni Air International, and Silver Airways. Visit apa1224.org for more information.

Contact:

Lena Melentijevic, (347) 208-2279

LMelentijevic@teamster.org

SOURCE Teamsters Local 1224

Share this article

- 80% of surveyed executives in EMEA say an AI-related incident reached their board or C-suite in the past year, with only 40% changing AI governance policy or frameworks in response.

- 75% of respondents expect AI agents to have some level of autonomy with respect to decisions by 2027, yet only 37% say their governance is designed to scale with agentic AI deployment.

- When surveyed organizations want to deploy AI faster than governance and compliance frameworks are prepared for, nearly 60 percent (56%) continue within agreed risk limits while governance adapts; a third (33%) delay deployment until governance is ready.

- Only 37% of respondents have a formal, board-reviewed quantification of the financial risks created by gaps in their AI governance.

LONDON, Oct. 14, 2026 /PRNewswire/ -- New research by IBM (NYSE: IBM) finds that AI-related incidents are reaching boardrooms across Europe and the Middle East among the organizations surveyed, but governance capabilities and risk accountability are not keeping pace with adoption of the technology.

Eight in ten executives surveyed say an AI-related incident – including an agent failure, data exposure, AI-driven decision error, or AI security breach – reached their board or C-suite in the past year. Yet fewer than half (40%) of those organizations cite a change to AI governance policy or framework in response.

When the pace of deploying AI outstrips governance and compliance frameworks readiness, rather than pause while governance adapts, the majority (56%) of executives surveyed report pressing ahead within agreed risk limits. Just a third delay deployment entirely until their governance is ready.

The survey, of more than 3,200 senior executives at organizations across eight countries in Europe and the Middle East, suggests governance policies will be tested further as AI agents take on more autonomous work. Thirty-five percent of respondents say they are running agentic AI in production today, yet three-quarters expect AI agents to have some level of autonomy towards decisions by 2027. Only 37% say their current governance system is designed to scale with agentic AI deployment.

Ana Paula Assis, IBM Senior Vice President and Chair, EMEA and APAC, said: "The AI debate has moved from adoption to governance and accountability. As organizations progress from AI assistants to autonomous agents, governance can no longer be treated as a compliance exercise. It has become a business requirement and value enabler.

The enterprises that can scale AI with accountability and trust will be postitioned to realize business value. That means governance must be built into how agents operate, with clear boundaries on what they can do, clear ownership when things go wrong, and controls that work in real-time."

Accountability & liability gap

Nearly all executives (98%) surveyed have formally assigned responsibility for AI risk at board level, including 26% with a dedicated board-level AI committee. Yet the research found no clear consensus on accountability for adverse outcomes from AI agents. An organization's CIO or CTO was the most frequently cited role with assigned responsibility for adverse outcomes from AI agents, selected by just 17% of all respondents.

Respondents' views on legal liability when an AI system causes significant harm were also divided: 20% say it should be shared proportionally between deployer and vendor, 19% say there should be a regulatory framework that does not yet adequately exist, and 14% say it should sit with the AI vendor or technology provider.

To manage increasingly autonomous AI agents making decisions without human approval at each step by 2027, executives expect to need formal legal or contractual frameworks defining AI vendor liability for agent failures (33%), defined human escalation thresholds (32%), real-time monitoring and audit trails of agent decisions and actions (30%) and the ability to immediately halt agent activity across the enterprise (29%).

Other key findings include:

- Measurement of financial risk exposure less established than board ownership: More than half (54%) of surveyed executives govern generative AI tools and agentic AI systems as distinct risk categories with separate governance frameworks and a further 38% apply the same core framework, but with additional controls to agentic AI. Measuring financial exposure from gaps in AI governance is less advanced: only 37% have a formal, board-reviewed quantification of the financial risk created by gaps in their AI governance.

- Supply chain risk: 54% of all respondents acknowledge gaps or limitations in how their governance framework covers the AI systems and models used by key vendors, technology partners and supply chain participants. Only 21% continuously monitor third-party AI risk and 13% apply independent assurance or certification requirements.

- Regulation shapes the pace regionally: In the EU, 41% of surveyed executives are accelerating governance investment ahead of the EU AI Act's high-risk obligations in December 2027, and a further 35% are on track with structured compliance plans. In the UK, sector regulator expectations are the most cited driver of AI governance investment (27%), while in Saudi Arabia and the UAE, national AI strategy requirements lead (61%).

Study methodology

The research was conducted by Censuswide on behalf of IBM among 3,221 executive management respondents, including C-level, at organizations with 1,000 or more employees in the UK, France, Germany, Italy, Spain, the Netherlands, Saudi Arabia and the UAE. The data was collected between 14 and 24 September 2026.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity, and service. Visit www.ibm.com for more information.

Media contact: 

Gregor Hastings

IBM EMEA Communications

[email protected]

SOURCE IBM

Share this article

Five-year collaboration framework aims to advance point-of-care diagnostics, clinical performance evaluation, and precision-medicine applications

LAS VEGAS and TORONTO, Oct. 14, 2026 /PRNewswire/ -- PurMinds Enterprises, Inc. (formerly Pacific Software, Inc.) (OTC: PFSF) ("PurMinds" or the "Company") today announced the signing of a collaboration agreement with SpectroChip Inc. ("SpectroChip"), a Taiwan-based developer of photonic-chip sensing and portable testing technologies, and Kaohsiung Municipal Siaogang Hospital ("Siaogang Hospital"), operated by Kaohsiung Medical University, to support teaching, research, and clinical validation of point-of-care (POC) diagnostic technologies and testing solutions.

The collaboration brings together SpectroChip's photonic chip-based portable testing technology, PurMinds' SwiftLabTM Platform and precision-medicine solutions, and Siaogang Hospital's clinical research capabilities. The parties intend to establish the joint "PurMinds / SpectroChip Global Clinical Validation Testing Center" for teaching, research, and clinical-validation activities, as a framework for evaluating diagnostic performance, assessing testing workflows, and advancing research into continuously improved POC performance, subject to review by an institutional review board (IRB), institutional approvals and applicable regulatory requirements.

Connecting diagnostic technology with clinical research

PurMinds' SwiftLabTM Platform is built around a full-spectrum laboratory-grade spectrometer shrunk onto a single, highly advanced photonic chip and housed inside the SpectroCision™ SPU-D100, a portable reader small enough to carry anywhere. The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a lab-grade quantitative result in five minutes or less, in clinics, pharmacies, community health centers, and at the patient's bedside. Clinical research and performance evaluation are important steps in assessing how diagnostic technologies and testing solutions perform in intended-use settings.

Under the collaboration, the parties will contribute complementary capabilities:

- PurMinds will lead the precision-medicine applications, clinical research collaboration, and access to international research and industry resources in its overall global commercialization strategy.

- SpectroChip will provide its photonic chip-based testing technology, together with technical documentation, training, and related support.

- Siaogang Hospital will provide an institutional setting for approved teaching, research, and clinical-validation activities, including research design, performance evaluation, testing-workflow assessment, and talent development.

Specific research projects will be established through separate written arrangements defining their scope, responsibilities, timelines, funding, and deliverables. Activities involving human participants, specimens, personal data, or medical-device clinical studies will proceed in accordance with applicable ethical, regulatory, and institutional requirements. The designation does not represent the establishment of a separate legal entity or dedicated physical facility.

By connecting technology development with institutional research capabilities, the collaboration aims to create a foundation for evaluating diagnostic applications and supporting PurMinds' development and commercialization activities.

Research and education support

Under the collaboration framework, SpectroChip has committed to providing Siaogang Hospital with NT$3 million (about US$94,000) in teaching and research funding over five years, generally at NT$600,000 per year, subject to the applicable agreement and institutional procedures. The funding is intended to support approved educational and research activities, which may include research consumables, testing, equipment maintenance, data analysis, research personnel, training, and academic exchange. The collaboration framework preserves the hospital's independence in its professional, clinical, research, and procurement decisions.

"This collaboration brings together SpectroChip's cutting-edge photonic chip technology, Siaogang Hospital's clinical research environment and PurMinds' precision-medicine platform and commercialization strategy," said Janet Qi, Founder and Chief Executive Officer of PurMinds. "Given the full-spectrum spectrometry embedded in our platform and its potential to develop an extended catalog of testing items, our vision is to connect with clinically relevant testing applications and the research needed to evaluate them."

"For over two decades, our team has worked to miniaturize spectrometer technology and make quantitative analysis possible through our proprietary photonic chip technology. This collaboration with PurMinds and Siaogang Hospital represents an important opportunity to bring our technology into a structured clinical research environment, where diagnostic performance and testing workflows can be systematically evaluated," said Dr. Cheng-Hao (Kevin) Ko, founder of SpectroChip and inventor of the SwiftLab Platform.

"Collaboration between healthcare institutions, technology developers, and market integrators is important to the responsible evaluation of emerging diagnostic technologies. We look forward to supporting appropriate teaching and research activities, evaluating diagnostic performance under approved study protocols, and contributing clinical perspectives to the development of point-of-care testing. All research activities will be conducted in accordance with applicable ethical, institutional, and regulatory requirements," said Chih-Hsing Hung, MD, PhD, Dean of Kaohsiung Municipal Siaogang Hospital.

About PurMinds Enterprises, Inc.

PurMinds Enterprises, Inc. (OTC: PFSF) exists to close the gap between precise answers from a central laboratory, which arrive days after the patient has gone home, and fast answers from rapid tests, which offer a single faint "yes or no" line and nothing more. At the heart of its SwiftLab™ Platform is a full-spectrum, laboratory-grade spectrometer shrunk onto a photonic chip and housed inside the SpectroCision™ SPU-D100, a fully portable reader small enough to carry anywhere without the need for recalibration. The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a quantitative result in five minutes or less. That capability stands on 17 peer-reviewed papers, 15 granted patents, and a trade-secret manufacturing process refined over 20 years.

One reader delivers every use case: comprehensive blood testing, veterinary diagnostics, roadside drug intoxication screening, specialized multiplex panels, and pathogen testing, all run on the same SpectroCision reader. Only the low-cost test cassette changes. Clinical uses are subject to regulatory clearance in each market. PurMinds holds an exclusive license to the SwiftLab Platform for the health and safety fields worldwide.

PurMinds began with a single ambition: to treat the brain. A company that means to treat the brain must be able to measure disease progression and therapeutic intervention, repeatedly, cheaply, and wherever the patient is, and that need brought PurMinds and SpectroChip together to build a quantitative point-of-care neurology panel. PurMinds holds its two drug candidates in a wholly owned subsidiary, PurQuest™ Therapeutics: PUR102, a botanical psilocybin, and PUR501, a preclinical non-hallucinogenic neuroplastogen.

The SpectroCision reader and PurMinds cassettes have not been cleared or approved by the United States Food and Drug Administration or licensed by Health Canada and are not available for clinical use in the United States or Canada.

For more information, visit www.purminds.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements concerning the collaboration among PurMinds, SpectroChip, and Siaogang Hospital; anticipated research, testing, and clinical-validation activities; the potential applications of point-of-care diagnostic technologies; the development and commercialization of diagnostic products; and the Company's business strategy.

Forward-looking statements are based on current expectations, assumptions, and estimates and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the ability to implement planned research activities, obtain required institutional and ethics approvals, meet regulatory requirements, demonstrate product performance, secure resources, and establish commercial relationships; that regulators may not clear, waive, or license the Company's products, or may do so later or with narrower claims than expected; that the Company depends on licenses and collaborations with third parties that could be lost or restricted; that the Company requires additional capital and may not obtain it on acceptable terms; and that the Company is a former shell company with a limited operating history, has not yet published audited financial statements, and has a small public float; as well as competition and general economic and market conditions.

The collaboration does not guarantee any particular research outcome, regulatory authorization, product commercialization, or financial result. No assurance can be given that the parties will complete planned activities within anticipated timelines or achieve their intended objectives. Readers should not place undue reliance on forward-looking statements. Except as required by applicable law, PurMinds undertakes no obligation to update forward-looking statements following the date of this release. This press release is not an offer to sell or a solicitation of an offer to buy any security.

SOURCE PurMinds Enterprises, Inc.

Share this article